AUTHOR=Martinez-Nunez Alfonso Enrique , Rozell Christopher J. , Little Simon , Tan Huiling , Schmidt Stephen L. , Grill Warren M. , Pajic Miroslav , Turner Dennis A. , de Hemptinne Coralie , Machado Andre , Schiff Nicholas D. , Holt-Becker Abbey S. , Raike Robert S. , Malekmohammadi Mahsa , Pathak Yagna J. , Himes Lyndahl , Greene David , Krinke Lothar , Arlotti Mattia , Rossi Lorenzo , Robinson Jacob , Bahners Bahne H. , Litvak Vladimir , Milosevic Luka , Ghatan Saadi , Schaper Frederic L. W. V. J. , Fox Michael D. , Gregg Nicholas M. , Kubu Cynthia , Jordano James J. , Cascella Nicola G. , Nho YoungHoon , Halpern Casey H. , Mayberg Helen S. , Choi Ki Sueng , Song Haneul , Cha Jungho , Alagapan Sankaraleengam , Dosenbach Nico U. F. , Gordon Evan M. , Ren Jianxun , Liu Hesheng , Kalia Lorraine V. , Hescham Sarah-Anna , Kusyk Dorian M. , Ramirez-Zamora Adolfo , Foote Kelly D. , Okun Michael S. , Wong Joshua K. 

TITLE=Proceedings of the 12th annual deep brain stimulation think tank: cutting edge technology meets novel applications

JOURNAL=Frontiers in Human Neuroscience

VOLUME=Volume 19 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2025.1544994

DOI=10.3389/fnhum.2025.1544994

ISSN=1662-5161

ABSTRACT=The Deep Brain Stimulation (DBS) Think Tank XII was held on August 21st to 23rd. This year we showcased groundbreaking advancements in neuromodulation technology, focusing heavily on the novel uses of existing technology as well as next-generation technology. Our keynote speaker shared the vision of using neuro artificial intelligence to predict depression using brain electrophysiology. Innovative applications are currently being explored in stroke, disorders of consciousness, and sleep, while established treatments for movement disorders like Parkinson’s disease are being refined with adaptive stimulation. Neuromodulation is solidifying its role in treating psychiatric disorders such as depression and obsessive-compulsive disorder, particularly for patients with treatment-resistant symptoms. We estimate that 300,000 leads have been implanted to date for neurologic and neuropsychiatric indications. Magnetoencephalography has provided insights into the post-DBS physiological changes. The field is also critically examining the ethical implications of implants, considering the long-term impacts on clinicians, patients, and manufacturers.